StaffAttract
  • Login
  • Create Account
  • Products
    • Private Ad Placement
    • Reports Management
    • Publisher Monetization
    • Search Jobs
  • About Us
  • Contact Us
  • Unsubscribe

Login

Forgot Password?

Create Account

Job title, industry, keywords, etc.
City, State or Postcode

Cell Therapy Lab & Clinical Trials Operations Associate

Nexcella, Inc. - Sacramento, CA

Apply Now

Job Description

Cell Therapy Lab & Clinical Trials Operations AssociateNexcella, IncSacramento, CAOn-site, full timeOur 3 Core Values • Intelligence• Integrity• InitiativeOur mission is to harness the immune system through innovative cell therapies and other modalities to deliver widely accessible cures. Patients are waiting!What You'll Do:Work closely with clinical trial operations team to coordinate local and central scientific laboratory activities for ongoing clinical trials.Work closely with research & development and cell therapy manufacturing team to facilitate day-to-day operations of a scientific laboratory, support research and development activities.Maintain supply of appropriate reagents and supplies to conduct scientific and clinical experiments.Support ongoing smooth execution of experimental and clinical research and development activities.Skills and Experience we look for:Recent graduate OK, 1-2 years of relevant experience preferredEducation:Bachelor's degreeNexcella, IncNexcella, Inc. is a subsidiary of Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a "digital filter" that filters out non-specific activation. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a registrational design. Interim results were presented at ASCO 2025 in an oral presentation by Heather Landau, M.D. of Memorial Sloan Kettering Cancer Center. NXC-201 has been awarded Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA. Learn more at and .

Created: 2025-10-05

➤
Footer Logo
Privacy Policy | Terms & Conditions | Contact Us | About Us
Designed, Developed and Maintained by: NextGen TechEdge Solutions Pvt. Ltd.